EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PPD's enterprise value is $19,856 Mil.
PPD's EBITDA for the trailing twelve months (TTM) ended in Sep. 2021 was $919 Mil. Therefore, PPD's EV-to-EBITDA for today is 21.60.
The historical rank and industry rank for PPD's EV-to-EBITDA or its related term are showing as below:
PPD'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 13.48 Med: 22.92 Max: 27.28
Current: 21.6
During the past 5 years, the highest EV-to-EBITDA of PPD was 27.28. The lowest was 13.48. And the median was 22.92.
PPD's EV-to-EBITDA is not ranked
in the Drug Manufacturers industry.
Industry Median: 14.03
vs PPD: 21.60
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-26), PPD's stock price is $47.28.
PPD's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2021 was $0.995. Therefore, PPD's PE Ratio for today is 47.52.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
PPD EV-to-EBITDA Historical Data
The historical data trend for PPD's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PPD's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PPD's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PPD's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PPD's EV-to-EBITDA falls into.
PPD's current Enterprise Value is $19,856 Mil.
PPD's EBITDA for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $919 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PPD (NAS:PPD) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
PPD's share price for today is $47.28.
PPD's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.995.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of PPD's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
PPD is a global contract research organization that provides clinical trial and laboratory services to pharmaceutical, device, and diagnostic firms. The clinical development services segment offers outsourced trial services, spanning early- and late-stage trials, as well as peri- and post-approval trials, and the laboratory services segment includes both advanced lab testing and central lab services. The company was taken private in 2011 and went public again in 2020.. Thermo Fisher Scientific announced it will acquire PPD for $17.4 billion, which is scheduled to close by the end of 2021.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PPD has been successfully added to your 